SUPPLEMENTARY INFORMATION In format provided by Czerepak and Ryser (MARCH 2008)
|
|
- Carmel Morrison
- 6 years ago
- Views:
Transcription
1 Table S1 US FDA drug approvals from January 2006 December 2007 Quarter Proprietary name Generic name Indication* Industry origin, innovation level 4Q 2007 Bystolic Nebivolol # Hypertension Erbitux Cetuximab Metastatic colorectal 2b cancer after failure of irinotecan and oxaliplatin, as a monotherapy Doribax Doripenem Complicated intraabdominal and complicated urinary tract infections Isentress Raltegravir HIV infection, in other antiretroviral therapies Ixempra Ixabepilone Metastatic or locally advanced breast cancer resistant to treatment with anthracycline, taxanes or capecitabine, as monotherapy or in capecitabine Kuvan Sapropterin # Phenylketonuria Mircera Methoxy Anaemia associated with polyethylene glycolepoetin beta chronic renal failure Nexavar Sorafenib Hepatocellular carcinoma 2b Omnaris Ciclesonide nasal Seasonal allergic rhinitis spray in 6 11 years old Renvela Sevelamer carbonate Control serum phosphorus in dialysis patients with chronic kidney disease (CKD) Tasigna Nilotinib Philadelphia chromosome-positive chronic myelogenous leukemia in patients who are resistant or intolerant to prior therapies Stavzor Valproic acid Seizures and manic episodes associated with bipolar disorder and to prevent migraines Voluven Hydroxyethyl Blood volume loss starch # following surgery 3Q 2007 ACAM 2000 Smallpox vaccine Vaccine for use in subjects at high risk of exposure
2 Afluria Influenza vaccine Prevent influenza types A and B in adults 18 years and older Azor Fixed-dose Hypertension combination of olmesartan and amlodipine EvaMist Estradiol Moderate to severe vasomotor symptoms due to menopause Evista Raloxifene Reduce risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for breast cancer Evithrom Human thrombin General haemostasis in Exelon Patch Rivastigmine surgery Mild to moderate Alzheimer s disease (AD) Exelon Rivastigmine Mild to moderate Parkinson s disease dementia LCP Fenofibrate Hyperlipidaemia and FenoChol hypertriglyceridaemia Sanctura XR Trospium chloride Overactive bladder Selzentry Maraviroc Treatment-experienced adult patients infected with CC chemokine receptor 5 (CCR5)-tropic HIV-1 Somatuline Lanreotide, depot Acromegaly Totect Dexrazoxane Accidental extravasation of anthracycline chemotherapeutics Zelnorm Tegaserod Women with irritable bowel syndrome with constipation or chronic idiopathic constipation Zingo Lidocaine powder, needle-free injection Pain associated with venous access procedures in children ages Q 2007 Altabax Retapamulin Impetigo AzaSite Azithromycin Bacterial conjunctivitis ophthalmic solution Extina Ketoconazole, topical Seborrheic dermatitis in immunocompetent H5N1 influenza virus vaccine H5N1 pandemic influenza vaccine patients Prevent influenza
3 HepaGam B Human hepatitis B immune globulin Prevent hepatitis B virus (HBV) reinfection in HBsAg-positive liver transplant patients Letairis Ambrisentan Pulmonary arterial hypertension Neupro Rotigotine Early stage Parkinson s disease Nuvigil Armodafinil Excessive sleepiness associated narcolepsy, obstructive sleep apnea/hypopnea syndrome and shift work sleep disorder Perforomist Formoterol fumarate Chronic obstructive pulmonary disease (COPD) Supprelin- LA Subcutaneous histrelin acetate implant Central precocious puberty Torisel Temsirolimus Advanced renal cell carcinoma Xyzal Levocetirizine dihydrochloride Seasonal and perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria Zyflo CR Zileuton Prevent and treat asthma 2a Prevent influenza in individuals 5-49 years of age 1Q 2007 CAIV-T Live attenuated cold-adapted trivalent influenza vaccine Exforge Combination of amlodipine and valsartan Hypertension Humira Adalimumab Moderate to severe Crohn s disease in patients not responding to conventional therapy Keppra Levetiracetam Adjunctive therapy, primary generalized tonic-clonic seizures in patients Lialda Mesalamine Induction of remission in patients with active, mild to moderate ulcerative colitis Olux-E Clobetasol propionate foam Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients ages 12 and older Soliris Eculizumab Paroxysmal nocturnal haemoglobinuria 2a
4 Sutent Sunitinib malate Advanced renal cell carcinoma, first-line treatment Tekturna Aliskiren Hypertension, monotherapy or in other anti-hypertensive agents Tykerb Lapatinib Advanced metastatic HER2-positive breast cancer in patients who have received prior therapy, in combination with capecitabine Vidaza Azacitidine Myelodysplastic syndromes (MDS) Vyvanse Lisdexamfetamine Paediatric attentiondeficit/hyperactivity disorder (ADHD) Yaz Ethinyl estradiol/ drospirenone Moderate acne in women who want an oral contraceptive for birth control 4Q 2006 Avastin Bevacizumab Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC), in carboplatin and paclitaxel as first-line treatment Byetta Exenatide Adjunctive therapy to improve blood sugar control in patients with type 2 diabetes who have not achieved adequate control on a thiazolidinedione Coreg CR Carvedilol Mild to severe heart failure Elestrin Estradiol gel Moderate to severe vasomotor symptoms associated with menopause Invanz Ertapenem Prevent surgical site infection following elective colorectal surgery in adults Invega Paliperidone, extended-release Januvia Sitagliptin phosphate Schizophrenia Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes, 4 2a 2b 2b
5 Omnaris Ciclesonide Seasonal and allergic rhinitis in patients 12 years of age and older Polyphenon Clindamycin External genital and E Ointment perianal warts Tyzeka Telbivudine Chronic HBV infection Veregen Kunecatechins, External genital and topical perianal warts Zolinza Vorinostat Cutaneous T-cell lymphoma, third-line therapy 3Q 2006 Atripla Fixed-dose HIV-1 infection combination of emtricitabine, tenofovir and efavirenz Elaprase Idursulfase Mucopolysaccharidosis II, Hunter syndrome Fentora Fentanyl Breakthrough cancer pain Noxafil Posaconazole Prevent invasive Aspergillus and Candida infections in immunocompromised patients at high risk for infection Pylera Triple-combination of biskalcitrate potassium, metronidazole and tetracycline Helicobacter pylori infection Vectibix Panitumumab Metastatic colorectal cancer in patients who have failed chemotherapy Verdeso Desonide, topical Mild to moderate atopic dermatitis Xolegel Ketoconazole, Seborrheic dermatitis topical Vivitrol Naltrexone Alcohol dependence 2Q 2006 Chantix Varenicline Smoking cessation Cubicin Daptomycin Bacteremia caused by Staphylococcus aureus, endocarditis caused by methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) Dacogen Decitabine MDS Daytrana Methyl-phenidate Paediatric ADHD 2b Exelon Rivastigmine Mild to moderate dementia associated with Parkinson s disease Lucentis Ranibizumab Wet age-related macular degeneration 2a
6 Myozyme Alglucosidase alfa Pompe s disease Opana Oxymorphone Pain Oracea Doxycycline Rosacea Orapred Prednisolone Paediatric asthma and reduce inflammation from various inflammatory conditions Prezista Darunavir HIV infection, 4 Revlimid Lenalidomide Newly diagnosed multiple myeloma, in dexamethasone Sprycel Dasatinib Chronic myelogenous leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia in patients with resistance or intolerance to prior therapy Thalomid Thalidomide Newly diagnosed multiple myeloma, in dexamethasone Tysabri Natalizumab Monotherapy, relapsing 2a forms of multiple sclerosis (MS) 1Q 2006 Amitizia Lubiprostone Chronic idiopathic constipation in adults Aranesp Darbepoietin alfa Chemotherapy-induced anaemia in patients with non-myeloid malignancies Azilect Rasagiline mesylate Parkinson s disease, as monotherapy and adjunct therapy to levodopa Eraxis Anidulafungin Esophageal candidiasis Erbitux Cetuximab Squamous cell carcinoma of the head and neck Exubera Inhaled insulin Type 1 and type 2 diabetes Ranexa Ranolazine Chronic angina Ralenza Zanamivir Prevent influenza in, 4 adults and children age five years or older Rituxan Rituximab Diffuse large B cell, CD20 positive, non- Hodgkin s lymphoma in anthracycline-based chemotherapy, as firstline treatment
7 Rituxan Rituximab Moderately to severely active rheumatoid arthritis in patients who have had an inadequate response to anti-tnf therapies, in combination with methotrexate Sutent Sunitinib malate Advanced renal cell carcinoma and gastrointestinal stromal tumors Vusion Miconazole, topical Candida-associated diaper dermatitis Zegerid Omeprazole Heartburn and other symptoms associated with gastroesophageal reflux disease (GERD), erosive esophagitis, duodenal ulcers and gastric ulcers, 4 * For full information of clinical indications, please refer to FDA approvals and/or company information. 1=biotech companies; 2=biotech/pharma alliances; 3=pharmaceutical companies; 4=acquired /licensed product from a biotech company; a=novel drug, new chemical structure; b=line extension; c=me-too. New Molecular Entities or New Biologics, not including imaging agents (21 in 2006; anticipated to be 18 in 2007). # An NME designation has not yet been given to nebivolol, hydroxyethyl starch and sapropterin by the FDA according to the FDA website, but is anticipated to be by some. Source: BioCentury reports (REFS 1 8) and 1. No Author listed. 1Q Stock Wrap-Up. BioCentury 14, No.15, 9 11 (2006). 2. No Author listed. 2Q Stock Wrap-Up. BioCentury 14, No. 29, (2006). 3. No Author listed. 3Q Stock Wrap Up. BioCentury 14, No. 43, (2006). 4. Edelson, S. 4Q Stock Wrap-Up. BioCentury 15, No. 1, 8 12 (2007). 5. No Author listed. 1Q Stock Wrap-Up. BioCentury 15, No. 15, 9 12 (2007). 6. Lawrence S. 2Q Stock Wrap-Up. BioCentury 15, No. 29, (2007). 7. Lawrence, S. 3Q Stock-Wrap-Up. BioCentury 15 No. 43, 9 12 (2007). 8. Lawrence, S. 4Q Stock Wrap-Up. BioCentury 16 No. 2, (2008).
Excellence in Care: New Drugs Released in 2006
Excellence in Care: New Drugs Released in 2006 Renee Acosta, R.Ph INDEPENDENT STUDY Health Professions Institute for Continuing Education Austin Community College The Austin Community College Health Professions
More informationNew Drugs of New Drug Applications Approved
New Drugs of 2006 97 New Drug Applications Approved 49 New Dosage Form 18 New Molecular Entity 12 New Manufacturer/Formulation 9 New Combination 4 New Biologic Entity 3 New Salt/Ester/Derivative 2 Rx-to-OTC
More informationSection I contains changes to the Highmark Select/Choice Formulary.
June 2007 2 nd Quarter Update: Highmark Drug Formulary Enclosed is the 2 nd Quarter 2007 update to the Highmark Drug Formulary and pharmaceutical management procedures. The Formulary and pharmaceutical
More informationAzacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded
Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from
More informationPharmacy and Medical Guideline Updates
STAT Bulletin PO Box 15013 Albany, New York 12212 August 2, 2010 Volume 8: Issue 19 To: All PCPs and Specialists Contracts Affected: All Lines of Business Pharmacy and ical Guideline Updates As a result
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationArea Drug and Therapeutics Committee Prescribing Supplement No 22 June 2008
Area Drug and Therapeutics Committee Prescribing Supplement No 22 In this issue Drugs currently being considered by SMC advice due on 09 ADTC decisions carried over from the previous bulletin in February
More informationArea Drug and Therapeutics Committee Prescribing Supplement No 16 May 2007
Area Drug and Therapeutics Committee Prescribing Supplement No 16 In this issue Drugs currently being considered by the SMC advice due on 11 June 07. Correction to the last edition (No 15) of the prescribing
More informationArea Drug and Therapeutics Committee Prescribing Supplement No 20 December 2007
Area Drug and Therapeutics Committee Prescribing Supplement No 20 In this issue Drugs currently being considered by SMC advice due on 14 January 2008. Lanarkshire Joint Formulary 2 nd edition November
More informationApril May For adults for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion.
April May 2014 Recommended for use within NHS Scotland April May 2014 aflibercept intravitreal (Eylea ) 954/14 For adults for the treatment of visual impairment due to macular oedema secondary to central
More informationNew Mexico Health Connections Drug Safety Updates. Drug Safety Updates Q Route of Administration. Action. Brand Name Generic Name Indications
Q4 2017 Advair Diskus salmeterol Asthma, COPD inhaler Advair HFA salmeterol Asthma inhaler Airduo Respiclick salmeterol Asthma inhaler Alecensa alectinib Non-Small Cell Lung Cancer Genentech announced
More informationPharmacotherapy Handbook
Pharmacotherapy Handbook Eighth Edition Barbara G. Wells, PharmD, HP, FCCP, BCPP Dean and Professor Executive Director, Research Institute of Pharmaceutical Sciences School of Pharmacy, The University
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationSection I contains changes to the Highmark Select/Choice Formulary.
September 2007 3 rd Quarter Update: Highmark Drug Formulary Enclosed is the 3 rd Quarter 2007 update to the Highmark Drug Formulary and pharmaceutical management procedures. The Formulary and pharmaceutical
More informationManufacturing and Marketing permission issued from SND Division from to
Manufacturing and Marketing permission issued from SND Division from 01.01.2018 to 31.05.2018. S.No Drug Name Composition Indication Date of Approval As a component of multi agent Pegaspargase Each vial
More informationHEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016
Selected 2016 Highlights Epidemiologic research on chronic kidney disease and fistula patency, solid and hematologic malignancies Health economics and outcomes research on beta3-agonist treatment for overactive
More informationDirectorate General of Health Services Office of Drugs Controller General (India) (Biological Division)
Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division) List of r-dna drug products approved in the country (Form 45 and 45A) from 1 st Jan 2015 to 30 th
More informationANNEX - List of the paediatric MAs/variations in 2014 i
ANNEX - List of the paediatric MAs/variations in 2014 i Tradename/ indication treatment of HIV 1 infection in paediatric patients in combination > 3 years PREZISTA/darunavir 12/02/2007 J TIVICAY/dolutegravir
More informationPast Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1
Appointment Date: Page 1 Chief Complaint: (Please write reason, symptoms, condition or diagnosis that prompts your appointment) Past Medical History PERSONAL SKIN HISTORY YES NO Yes - Details Melanoma
More informationPEI Drug Programs. Issue February 20, 2009
PEI Drug Programs Formulary Update Issue 09-01 February 20, 2009 New medications for the treatment of cancer, chronic obstructive pulmonary disease (COPD), osteoporosis, and HIV/AIDS have been approved
More informationFREEDOM OF INFORMATION SOUTH EAST SCOTLAND CANCER NETWORK
Dear Date 06/02/09 Your Ref Our Ref RM/1220 Enquiries to Richard Mutch Extension 89441 Direct Line 0131-536-9441 Direct Fax 0131-536-9009 Email richard.mutch@lhnhslothian.scot.nhs.uk FREEDOM OF INFORMATION
More informationBarbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi
Barbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi Joseph T. DiPiro, PharmD, FCCP Panoz Professor of Pharmacy, College
More informationEVIDENCE-BASED VITAMIN AND MINERAL USAGE SUMMARY TABLE (APRIL 2002)
Acne Acrodermatitis Enteropathica Adrenal Support Age Related Cognitive Decline Alcoholism/Alcohol Withdrawal Alzheimer's Disease Amenorrhoea Anaemia Angina Anorexia Nervosa Anxiety Asthma Atherosclerosis
More informationRationale for Decision Excluded Generic OTC equivalent available (Flonase Allergy Relief) Medicare status (if differs)
BLUE SHIELD OF CALIFORNIA FIRST QUARTER 2015 FORMULARY AND MEDICATION POLICY UPDATES EFFECTIVE MARCH 19, 2015 The Blue Shield of California (BSC) Pharmacy and Therapeutics (P&T) Committee, consisting of
More informationStratified medicine in practice: Review of predictive biomarkers in European Medicines Agency (EMA) indications
Stratified medicine in practice: Review of predictive biomarkers in European Medicines Agency (EMA) indications Kinga Malottki, Mousumi Biswas, Jon Deeks, Richard Riley, Charles Craddock, Lucinda Billingham
More informationPfizer Pipeline. August 9, 2012
Pfizer Pipeline August 9, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information
More informationChanges from Third Quarter Flash Report for the Fiscal Year ending March 2015 announced on February 3, 2015 *1: Marketing authorization of Onoact 150
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2015 Supplemental Information Status of Development Pipeline as of May 12, 2015 I. Main Pipelines Other than ONO-4538 ⅰ. Developments Status
More informationVectibix (panitumumab) will be considered medically necessary when all of the following criteria are met:
What s New Medical Pharmaceutical Policy November 2017 Updates MBP 40.0 Orencia IV (abatacept)- New Indication Orencia IV (abatacept) will be considered medically necessary when all of the following criteria
More informationEvolve180 / Ideal Northwest Health Profile
Evolve180 / Ideal Northwest Health Profile ABOUT YOU First Name: Last Name: Address: City: State: Zip: Phone: Email: Date of Birth: Age: Height: Occupation: How did you find out about our program? Marital
More informationDrugs That Require Prior Authorization (PA) Before Being Approved for Coverage
Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage You will need authorization by your UA Medicare Part D Prescription Drug Plan before filling prescriptions for the drugs shown
More informationMerck Pipeline. November 1, 2017
Merck Pipeline November 1, 2017 Lead-in Language The chart below reflects the Company s research pipeline as of November 1, 2017. Candidates shown in Phase 3 include specific products and the date such
More informationList of Recombinant DNA based Drugs Approved in the Country (Form-45) 1st Jan st Dec 2013
S.No. 1 Name of the firm Ferring Date of Approval 4-Apr-10 License No. Import-450/10 2 G.C.Chemie 23-Jun-10 IMP-572/10 3 R.K. Medicare 9-Sep-10 IMP-783/10 4 5 List of Recombinant DNA based Drugs Approved
More informationNICE TA Adherence Check List
NICE TA Adherence Check List KEY NICE TA PAS Not Terminated Indication Technology Appraisal carried out by the National Institute of Clinical Excellence - It is the process by which new and existing drugs
More informationReview of predictive biomarkers in European Medicines Agency (EMA) drugs
Review of predictive biomarkers in European Medicines Agency (EMA) drugs Kinga Malottki, Mousumi Biswas, Jon Deeks, Richard Riley, Charles Craddock, Lucinda Billingham 10 February 2012 Objectives What
More informationRayos Prior Authorization Program Summary
Rayos Prior Authorization Program Summary FDA APPROVED INDICATIONS AND DOSAGE FDA-Approved Indications: 1 Agent Indication Dosage Rayos (prednisone delayedrelease tablet) as an anti-inflammatory or immunosuppressive
More informationManufacturing and Marketing permission issued from SND Division from to
Manufacturing and Marketing permission issued from SND Division from 01.01.2018 to 04.07.2018. S.No Drug Name Composition Indication Date of Approval As a component of multi agent Pegaspargase Each vial
More informationStep Therapy Approval Criteria
Effective Date: 07/01/2015 This document contains for the following medications: 1. Ambien CR (zolpidem ER) 2. Chantix Continuing Month (varenicline) 3. Chantix Starting Month (varenicline) 4. Cymbalta
More informationTerm & Universal Life Guidelines - Simplified
- G.U.L. AIDS Alcoholism Within past 4 years: Within past 4 years: Within past 5 years: After 5 years, without relapse, no current use: : After 5 years since treatment: Less than 5 years: POSSIBLE STANDARD
More informationCUMULATIVE ILLNESS RATING SCALE (CIRS)
CUMULATIVE ILLNESS RATING SCALE (CIRS) The CIRS used in this protocol is designed to provide an assessment of recurrent or ongoing chronic comorbid conditions, classified by 14 organ systems. Using the
More informationPrescribing Guide Standard Control Change Summary Report Effective (Standard Drug List Reflects Removals)
This report highlights all changes (additions, deletions and removals) to the CVS Caremark Prescribing Guide Standard Control. ADDITIONS: Brand Agents: Austedo (deutetrabenazine) tablet Estring (estradiol)
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationJanuary 2018 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed
More informationSimponi / Simponi ARIA (golimumab)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 6 Last Review Date: September 15, 2016 Simponi / Simponi
More informationTarget date to recruit patients agreed? Target range minimum. Target range maximum. Agreed 1 1 Agreed 01/01/ /01/2016 Recruitment Finished
No REC Reference IRAS No Title Target number of patients agreed? Target range minimum Target range maximum Target date to recruit patients agreed? Planned Recruitment end date No of patients recruited
More informationSCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2018
January 201 DATE DAY TIME TOPICS TOTAL January 04 1. Understanding Fibromyalagia 2. Diabetes and Cardiovascular Disease 3. Prostate Cancer 4. Hepatitis C 5. Understanding Hepatitis B January 11 1. Dysphagia
More informationSCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2018 WALK INS ARE ACCEPTED BUT WE ADVISE STUDENTS TO PRE-REGISTER BEFORE THURSDAY
SCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs January 201 DATE DAY TIME TOPICS January 04 January 11 January 1 January 25 9:00AM 9:00AM 9:00AM 9:00AM 1. Understanding Fibromyalagia 2. Diabetes
More informationPremium Specialty: Pediatrics
Premium Specialty: Pediatrics Credentialed Specialties include: Adolescent Medicine, Pediatric Adolescent, and Pediatrics This document is designed to be used in conjunction with the UnitedHealth Premium
More informationSCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2019
January 2019 DATE DAY TIME TOPICS TOTAL January 03 1. Alcoholism 2. Nutrition for the Elderly 3. Uterine Fibroids 4. HIPAA 5.Arthritis 6. Childhood Obesity January 10 1. Understanding Epilepsy: Latest
More information29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients?
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been: accepted for use in the NHSScotland
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Hwang TJ, Bourgeois FT, Seeger JD. Drug safety in the digital
More information03 May 2016 Page 1 of 5. How does the NHS board decide which new medicines to make available for patients?
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been: accepted for use in the NHSScotland
More informationDrugs approved from 1st January 2015 till present. S.NO Name Of Drug Indication Date of Approval 1 Levocetirizine ODS 2.5mg /5mg (Additional
Drugs approved from 1st January 2015 till present S.NO Name Of Drug Indication Date of 1 Levocetirizine ODS 2.5mg /5mg dosage form) For allergic rhinitis and chronic urticaria. 14.01.15 2 Decitabine Injection
More informationAn D. Nguyen, MD Curriculum Vitae
OFFICE/ BUSINESS ADDRESS: Pacific Shores Medical Group 19582 Beach Blvd, Suite 212 Huntington Beach, CA 92648 Phone: (714) 252-9415 Fax: (714) 963-8407 ADDITIONAL OFFICE: 16300 Sand Canyon Avenue, Suite
More informationUniversity of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan
University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More informationPharmacy Prep. Qualifying Pharmacy Review
Pharmacy Prep 2014 Misbah Biabani, Ph.D Director, Tips Review Centres 5460 Yonge St. Suites 209 & 210 Toronto ON M2N 6K7, Canada Luay Petros, R.Ph Pharmacy Manager, Wal-Mart, Canada 1 Disclaimer Your use
More informationActive Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG
More informationFORESTERS: COLUMBIAN FINANCIAL GROUP: Smart U.L. Strong Foundation. Safe Shield. After 5 years, without relapse, no current use: ACCEPT
AI Alcoholism Within past 4 years: Within past 4 years: Within past 5 years: After 5 years, without relapse, no current use: Within past 10 years: Alcohol Abuse: After 5 years since last treatment and
More informationHSCT - Minimum Essential Data - A FOLLOW UP REPORT - ANNUAL
CIC: HSCT - Minimum Essential Data - A FOLLOW UP REPORT - ANNUAL Disease PRIMARY DISEASE DIAGNOSIS Centre Identification EBMT Code (CIC): Hospital: Contact person: Unit: Email: Patient Data Date of this
More informationLECOM Health Ophthalmology
Patient Name: Date of Birth: New Patient Questionnaire Your answers will be used by your healthcare provider get an accurate history of your medical conditions and ocular concerns. If you are uncomfortable
More informationAvastin Sample Coding
First- and Second-line Metastatic Colorectal Cancer C18.0 Malignant neoplasm of the cecum C18.1 Malignant neoplasm of appendix C18.2-C18.9 C19 C20 C21.8 Malignant neoplasm of the colon, various sites Malignant
More informationField Underwriting Quickview
Field Underwriting Quickview For a selected list of medical conditions, the Field Underwriting Quickview outlines possible classifications and the circumstances when coverage may not be. For coverage provided
More informationPfizer Pipeline. November 8, 2012
Pfizer Pipeline November 8, 2012 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information
More informationHow much do you know about illnesses or health problems for your parents, grandparents, brothers, sisters, and/or children? 1 A lot Some None at all
Family Health History Please answer each question as honestly as possible. There are no right or wrong answers to nay of the questions. It is important that you answer as many questions as you can. We
More informationCHRONIC TREATMENT GUIDELINES
CHRONIC TREATMENT GUIDELINES REGISTRATION OF CHRONIC CONDITIONS You can only access benefits for chronic medication, as listed below, if your prescribing/treating doctor or pharmacist registers your chronic
More informationAre Specialty Pharmacy Drugs Worth the Cost? How Companies Can Make Them More Affordable.
Are Specialty Pharmacy Drugs Worth the Cost? How Companies Can Make Them More Affordable. BACKGROUND Your Host: Eric Bricker, MD Co-Founder & Chief Medical Officer - Compass Professional Health Services
More informationAnnual Flash Report (unaudited) Fiscal Year ended March 31, 2017
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017 Supplemental nation Status of Development Pipeline as of May 8, 2017. Main Status of Development Pipelines (Oncology) 1. Development Status
More informationCHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER
RAND WATER MEDICAL SCHEME RAND WATER MEDICAL SCHEME CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER LIST OF CHRONIC CONDITIONS Conditions covered under s chronic medication benefit are detailed below.
More informationNEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2016/17
New Medicine Product/Device Endorsement Categories NEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2016/17 A B C D E F recommended
More informationSASKATCHEWAN FORMULARY BULLETIN. Update to the 60th Edition of the Saskatchewan Formulary
Saskatchewan Ministry of Health July 1, 2010 Drug Plan and Extended Benefits Branch Bulletin #124 ISSN 1923-077X SASKATCHEWAN FORMULARY BULLETIN Update to the 60th Edition of the Saskatchewan Formulary
More informationICD-9-CM CODING FUNDAMENTALS CODING EXERCISES
Steps to Accurate Coding Underline the main term, then locate code: Stenosis of Carotid Artery Transient Ischemic Attack Gastrointestinal hemorrhage Degenerative Joint Disease Coronary Artery Disease Alcoholic
More informationErbitux. Erbitux (cetuximab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.84 Subject: Erbitux Page: 1 of 6 Last Review Date: December 2, 2016 Erbitux Description Erbitux (cetuximab)
More informationDrug Formulary Update, July 2016 Commercial and State Programs
Drug Formulary Update, July 2016 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,
More informationArea Drug and Therapeutics Committee Prescribing Supplement No 31 - June 2009
Area Drug and Therapeutics Committee Prescribing Supplement No 31 - In this issue Drugs currently being considered by SMC advice due on 13 th July 2009 Drug Safety Update STOP PRESS Clopidogrel and PPIs
More informationPfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals
In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be Yes : Does the activity align with Pfizer s areas of interest? (listed
More informationMedicine Condition being treated NHSGGC Decision Date of decision. 18 June 2018 Page 1 of 5
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available in a health board only after it has been: accepted for use in by the Scottish Medicines
More informationAvastin (bevacizumab) DRUG.00028, CG-DRUG-68
Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved
More informationMerck Pipeline. August 1, 2018
Merck Pipeline August 1, 2018 Lead-in Language The chart below reflects the Company s research pipeline as of August 1, 2018. Candidates shown in Phase 3 include specific products and the date such candidate
More informationCurriculum Vitae, Joseph J. Savon, M.D.
CONTACT INFORMATION: Joseph J. Savon, M.D. Hassman Research Institute, LLC. 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009 Site Selection and Information: Bobbie Theodore, Alliance
More informationAdvanced Control Formulary Change Summary Report Effective
This report highlights all changes (additions, deletions, and removals) to the CVS Caremark Advanced Control Formulary ADDITIONS: Brand Agents: Austedo (deutetrabenazine) tablet Cystagon (cysteamine bitartrate)
More informationList of Qualifying Conditions
List of Qualifying Conditions Cancer Conditions 1) Adrenal cancer 2) Bladder cancer 3) Bone cancer all forms 4) Brain cancer 5) Breast cancer 6) Cervical cancer 7) Colon cancer 8) Colorectal cancer 9)
More informationNCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and
More informationDevelopment status of ONO-4538(nivolumab)1
Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1
More informationPerformance Drug List Change Detail Report Effective (Standard Drug List Reflects Removals)
This report highlights all changes (additions and deletions) to the CVS Caremark Performance Drug List. ADDITIONS: Brand Agents: Abilify (aripiprazole) Antipsychotics/Atypicals Abilify is indicated for
More informationA Review of FDA PRO Labeling ( ) Ari Gnanasakthy RTI Health Solutions
A Review of FDA PRO Labeling (2011-2015) Ari Gnanasakthy RTI Health Solutions SEVENTH ANNUAL PATIENT-REPORTED OUTCOME (PRO) CONSORTIUM WORKSHOP April 27-28, 2016 Silver Spring, MD Disclaimer The views
More informationTargeted Therapy Vijay Narang
25 Volume 1, Issue 1, January 2013, Online: Targeted Therapy Vijay Narang ABSTRACT This is a review on targeted therapy that blocks the growth and spread of cancer by interfering with specific molecules
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationMedical Reference Library Table of Contents
Medical Reference Library Table of Contents Alcoholism Anemia Anxiety Abdominal Aortic Aneurysm Asthma Atrial Fibrillation Attention Deficit Hyperactivity Disorder (ADHD) Barrett s Esophagus Bipolar Disorder
More informationMrs. Isabelle GAUDIN 22 years experience in Clinical Research LEAD CRA / SENIOR CLINICAL RESEARCH ASSOCIATE
Sté Aid ARC 36, Comba dels Martirs 11570 PALAJA FRANCE Fax : +33 4 68 47 03 52 Mob : +33 6 14 68 71 71 E-mail : isabelle.gaudin@aidarc.com Mrs. Isabelle GAUDIN 22 years experience in Clinical Research
More informationIndustry Company Products Pipeline Risks/Catalysts Valuation Q&A. Agenda
Industry Company Products Pipeline Risks/Catalysts Valuation Q&A Agenda 1 Pharmaceutical/Biotech Pharmaceutical companies Simple molecules made by chemical process taken orally Biotech companies Complicated
More informationDATE OF BIRTH: MELANOMA INTAKE
MELANOMA INTAKE GENERAL INFORMATION How was your first diagnosed? (Check the diagnosis that describes your condition.) Melanoma Merkel Cell Carcinoma Squamous Cell Carcinoma Basal Cell Carcinoma Other
More informationHMSA Provider Bulletin
HMSA Provider Bulletin T H E H M S A P L A N F O R Q U E S T M E M B E R S Bulletin Q09-06 December 1, 2009 Seasons greeting to you and your staff! As the holidays approach, we look forward to the many
More informationSupplementary materials
Supplementary materials Table S1 Patient comorbidities by diagnosis Total Asthma n (%) 5348 (148.4) COPD n (%) 4563 (143.4) ACOS n (%) 469 (197.9) No other comorbidities 95 (26.4) 614 (19.3) 27 (11.4)
More informationCurriculum Vitae, Steven H. Reynolds, D.O. Steven H. Reynolds, D.O. Collaborative Neuroscience Network, LLC.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationCancerPACT Cancer Patients Alliance for Clinical Trials
TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Salinas Valley Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal
More informationCOMMERCIAL APIs. S. No Molecule Name Therapeutic Category USDMF EDMF CEP IH
1 Abacavir Sulphate Antiretroviral - * - 2 Abiraterone Acetate Oncology - - - 3 Albendazole Anti-infective - - - 4 Albuterol Sulphate Respiratory - - 5 Alendronate Sodium Trihydrate Metabolic Disorder
More informationJ. Van Lier Ribbink, M.D., F.A.C.S. Center for Endocrine and Pancreas Surgery at Honor Health
J. Van Lier Ribbink, M.D., F.A.C.S. Center for Endocrine and Pancreas Surgery at Honor Health Patient Clinical Information Questionnaire 1.0 Date of Questionnaire Completion; / / 2.0 Patient Data 2.1 Name:
More informationIn your own words, please write the reason you are here. Please be specific, putting in dates as necessary. Use the back of the form if needed.
Name: SS# In your own words, please write the reason you are here. Please be specific, putting in dates as necessary. Use the back of the form if needed. Patient Medical, Surgical and Family History Review
More information